Molecular Testing for Intestinal Protozoa: How a Laboratory Developed Test Compares to One That Is FDA-Cleared Presented by Dr Susan Madison-Antenucci Lab Chief of Bloodborne and Parasitic Diseases, New York State Department of Health, Wadsworth Center Assistant Professor – Biomedical Sciences. Assistant Professor – Environmental Health Sciences, College of Integrated Health Sciences, University at Albany.…

Implementation of pan-enteric PCR screening at a UK general district hospital – benefits, pitfalls and lessons learnt Presented by Elisabetta Savanco Senior Biomedical Scientist in Medical Microbiology at Blackpool Teaching Hospitals NHS Foundation Trust Gastroenteritis is a significant socioeconomic burden. It is crucial to identify or exclude infectious causes of gastroenteritis, as this informs treatment…

Genetic Signatures’ CEO, Dr John Melki was recently interviewed by David Tasker, Managing Director of Chapter One Advisors for TechInvest Magazine.

Genetic Signatures’ CEO- Dr. John Melki speaking at TechKnow Invest Roadshow which was held in Queensland and Melbourne Australia August 2023

Genetic Signatures’ CEO- Dr. John Melki speaking at TechKnow Invest Roadshow- November 2022

Genetic Signatures’ CEO Dr John Melki was recently interviewed by Nadine Blayney from AusBiz about the Company’s unique 3base® technology, its advantages for detecting infectious diseases, the development pipeline, revenue sources, and plans for further investment and expansion in key international markets.

Channel 9 interviews our customer SydPath, taking a look at their increased testing capabilities in response to the COVID-19 outbreak in NSW, implementing our high-throughput testing technology for respiratory infection

Genetic Signatures’ CEO- Dr. John Melki speaking at ASX Small and Mid-Cap Conference held in Sydney Australia September 2018